PL366696A1 - Przeciwzapalne alkohole tłuszczowe oraz estry kwasów tłuszczowych użyteczne jako nośniki antygenów - Google Patents

Przeciwzapalne alkohole tłuszczowe oraz estry kwasów tłuszczowych użyteczne jako nośniki antygenów

Info

Publication number
PL366696A1
PL366696A1 PL02366696A PL36669602A PL366696A1 PL 366696 A1 PL366696 A1 PL 366696A1 PL 02366696 A PL02366696 A PL 02366696A PL 36669602 A PL36669602 A PL 36669602A PL 366696 A1 PL366696 A1 PL 366696A1
Authority
PL
Poland
Prior art keywords
inflammatory
antigen
fatty acid
acid esters
esters useful
Prior art date
Application number
PL02366696A
Other languages
English (en)
Inventor
Irun R. Cohen
Meir Shinitzky
Raanan Margalit
Original Assignee
Yeda Research And Development Co.Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research And Development Co.Ltd. filed Critical Yeda Research And Development Co.Ltd.
Publication of PL366696A1 publication Critical patent/PL366696A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL02366696A 2001-04-11 2002-04-11 Przeciwzapalne alkohole tłuszczowe oraz estry kwasów tłuszczowych użyteczne jako nośniki antygenów PL366696A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL14253601A IL142536A0 (en) 2001-04-11 2001-04-11 Carriers for therapeutic preparations for treatment of t-cell mediated diseases

Publications (1)

Publication Number Publication Date
PL366696A1 true PL366696A1 (pl) 2005-02-07

Family

ID=11075313

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02366696A PL366696A1 (pl) 2001-04-11 2002-04-11 Przeciwzapalne alkohole tłuszczowe oraz estry kwasów tłuszczowych użyteczne jako nośniki antygenów

Country Status (17)

Country Link
US (1) US20040247604A1 (pl)
EP (1) EP1408951B1 (pl)
JP (1) JP2004526757A (pl)
KR (1) KR20030096311A (pl)
CN (1) CN1327898C (pl)
AT (1) ATE453409T1 (pl)
AU (1) AU2002307767B2 (pl)
CA (1) CA2442943A1 (pl)
DE (1) DE60234927D1 (pl)
HU (1) HUP0303796A3 (pl)
IL (2) IL142536A0 (pl)
MX (1) MXPA03009342A (pl)
NO (1) NO20034557L (pl)
NZ (1) NZ528783A (pl)
PL (1) PL366696A1 (pl)
WO (1) WO2002083058A2 (pl)
ZA (1) ZA200307784B (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
SI1509618T1 (sl) 2002-05-13 2009-02-28 Arexis Ab Avtoimunska stanja in defekti NADPH oksidaze
WO2004000333A1 (en) * 2002-06-20 2003-12-31 Astion Dermatology A/S Novel complexes of fatty acid esters of polyhydroxyalkanes and pyridine carboxy derivatives
CN100582085C (zh) * 2002-10-10 2010-01-20 耶达研究及发展有限公司 脂肪醇的碱性酯及它们作为抗炎药或免疫调节剂的用途
US20050158329A1 (en) 2004-01-21 2005-07-21 Ghosh Swapan K. Novel phytol derived immunoadjuvants and their use in vaccine formulations
EP1740169B1 (en) * 2004-04-24 2012-09-05 Enzychem Lifesciences Corporation Immunomoduating agent, anti-cancer agent and health food containing monoacetyldiacylglycerol derivatives
KR100594972B1 (ko) * 2004-11-06 2006-07-03 여진환 다목적 낚시용 의자
EP1917976B1 (en) 2005-08-01 2011-03-16 Hisamitsu Pharmaceutical Co. Inc. Adjuvant or pharmaceutical preparation for transdermal or transmucosal administration
JP5275047B2 (ja) * 2007-01-31 2013-08-28 久光製薬株式会社 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
WO2008106091A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Use of long-chain alcohol derivatives for the treatment of alopecia areata
WO2008106092A1 (en) 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec- 9- (z) enyl ester, their salts and their uses
WO2012115222A1 (ja) 2011-02-25 2012-08-30 久光製薬株式会社 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
PL405505A1 (pl) * 2013-09-30 2015-04-13 Warszawski Uniwersytet Medyczny Zastosowanie pochodnej kwasu diaminodikarboksylowego jako inhibitora aktywności biologicznej IL-15 I IL-2
ES2744454T3 (es) 2013-10-31 2020-02-25 Hisamitsu Pharmaceutical Co Composición de adyuvante
CN108853066A (zh) * 2018-09-20 2018-11-23 成都中医药大学 链式脂肪醇在制备抗炎、镇痛药物中的用途
CN112168812B (zh) * 2019-07-02 2022-07-08 瑞微(深圳)生物科技有限公司 棕榈油酸用于制备预防或治疗炎症性疾病的组合物的用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2984764A (en) * 1948-12-20 1961-05-16 Raytheon Co Electron discharge devices of the magnetron type
US3592930A (en) * 1968-07-19 1971-07-13 Syntex Corp Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle
US4152423A (en) * 1971-11-19 1979-05-01 Agence Nationale De Valorisation De La Recherche (Anvar) Immunological agents
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5194451A (en) * 1989-11-02 1993-03-16 Katz David H Systemic anti-inflammatory treatment
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US5817629A (en) * 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
WO1996028470A2 (en) * 1995-03-09 1996-09-19 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
IL114458A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev Therapeutic preparations for treatment of T cell mediated diseases
ES2277339T3 (es) * 1995-11-30 2007-07-01 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Vacuna con adyuvante de aceite y metodo para su preparacion.
TW355153B (en) * 1996-05-21 1999-04-01 Toshiba Machine Co Ltd A method for leveling abrasive cloth and device for the same
AU731692C (en) * 1996-10-11 2001-10-11 Scarista Limited Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
US5910306A (en) * 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US6210700B1 (en) * 1997-01-14 2001-04-03 Novartis Nutrition Ag Enhancement of transplant graft survival through nutritional immunomodulation with omega-9 fatty acid dietary supplement therapy
US6242426B1 (en) * 1997-07-25 2001-06-05 Avigen, Inc. Induction of immune response to antigens expressed by recombinant adeno-associated virus
US6114337A (en) * 1998-11-27 2000-09-05 Pugliese; Peter T. Zwitteronic-fatty acid compounds having anti-inflammatory properties
EP0919230A1 (en) * 1997-12-01 1999-06-02 Societe Des Produits Nestle S.A. NMIFA's as anti-inflammatory agents in superficial mammal tissues
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
US6118020A (en) * 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
CN100582085C (zh) * 2002-10-10 2010-01-20 耶达研究及发展有限公司 脂肪醇的碱性酯及它们作为抗炎药或免疫调节剂的用途

Also Published As

Publication number Publication date
WO2002083058A2 (en) 2002-10-24
WO2002083058A3 (en) 2004-02-26
EP1408951B1 (en) 2009-12-30
CN1514736A (zh) 2004-07-21
HUP0303796A3 (en) 2011-03-28
KR20030096311A (ko) 2003-12-24
ZA200307784B (en) 2004-10-06
ATE453409T1 (de) 2010-01-15
EP1408951A4 (en) 2004-08-18
JP2004526757A (ja) 2004-09-02
MXPA03009342A (es) 2004-02-12
IL158226A (en) 2008-11-03
AU2002307767B2 (en) 2007-08-30
US20040247604A1 (en) 2004-12-09
CA2442943A1 (en) 2002-10-24
NZ528783A (en) 2005-10-28
EP1408951A2 (en) 2004-04-21
CN1327898C (zh) 2007-07-25
IL142536A0 (en) 2002-03-10
DE60234927D1 (de) 2010-02-11
HUP0303796A2 (hu) 2004-03-01
NO20034557D0 (no) 2003-10-10
NO20034557L (no) 2003-12-05

Similar Documents

Publication Publication Date Title
EP1408951A4 (en) ANTI-FLAMMABILITY FATTY ALCOHOLS AND FATTY ACID ESTERS AS ANTIGENS
PL366586A1 (pl) Alkohole tłuszczowe oraz estry kwasów tłuszczowych użyteczne w leczeniu stanu zapalnego
DK1138325T3 (da) Anvendelse af syntetiske triglycerider på basis af konjugeret linolsyre til fremstilling af midler til støtte for tumorbehandlingen
BRPI0718997A2 (pt) Processo para preparar ésteres de alquila de ácidos graxos e acroleína a partir de triglicerídeos.
ES2422306T3 (es) Procedimiento mejorado para la preparación continua de (met)acrilatos de alquilo con un reciclamiento múltiple del catalizador
DK1121928T3 (da) Sammensætninger indeholdende phytosterol- og policosanolestere af fedtsyrer til reduktion af niveauet af blodcholesterol og -triglycerider
DK76889D0 (da) Fremgangsmaade til fremstilling af organiske forbindelser
PT1296670E (pt) Combinacoes terapeuticas de acidos gordos
AU2002334009A1 (en) Oral pharmaceutical composition comprising an active principle capable of being subjected to high effect during its first passage through the intestine
AR036685A1 (es) Un procedimiento para la preparacion de esteres policarboxilicos aliciclicos a partir de esteres parciales de acidos policarboxilicos aromaticos
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
EP1789462B8 (de) Verfahren zur herstellung von (poly-c2-c4-alkylenglykol)-mono(meth)acrylsäureestern
ES2143067T3 (es) Procedimiento para la preparacion de esteres acrilicos refinados.
FR2829491B1 (fr) Procede de preparation des hydroxy-acides gras insatures et de leurs esters, leur utilisation comme agent anti-collagenase
AU2001281415A1 (en) Enhancement of the action of central and peripheral nervous system agents
FR2743084B1 (fr) Procede de fabrication de produits solides par esterification des acides gras libres en presence de catalyseurs acides
AU2002213634A1 (en) Method for the production of fatty acid esters of lower alcohols
JP2004526757A5 (pl)
FR2843124B1 (fr) Procede de preparation d'acides gras polyinsatures libres et de leurs metabolites d'oxydation
AR023253A1 (es) Procedimiento para la preparacion de esteres de acido hidroximetiltiobutirico
MXPA03009493A (es) Preparacion de acidos carboxilicos insaturados y esteres de acido carboxilico insaturados a partir de alcanos y/o alquenos.
RU2524779C2 (ru) Сложный эфир диола с полиненасыщенной жирной кислотой как средство против угрей (акне)
NO20031225L (no) Fremgangsmåte for fremstilling av råstoffer for utvinning av konjugert linolsyre
BR9608732A (pt) Método para a purificação de um gás inerte enquanto se preparando ésteres de alquila inferior
JPS53105417A (en) Preparation of acrylic acid esters or methacrylic acid esters

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)